Yi Gong1, Rui Chen2, Xi Zhang3, Zhong Min Zou4, Xing Hua Chen3. 1. Department of Hematology, Xinqiao Hospital, The Third Military Medical University, Chongqing 400037, China; Department of Hematology-oncology, Chongqing Cancer Institute/Hospital, Chongqing 400030, China. 2. Department of Pathology, Chongqing Cancer Institute/Hospital, Chongqing 400030, China. 3. Department of Hematology, Xinqiao Hospital, The Third Military Medical University, Chongqing 400037, China. 4. Institute of Toxicology, School of Preventive Medicine, The Third Military Medical University, Chongqing 400038, China.
Abstract
OBJECTIVE: To investigate the risk stratification of aggressive B cell lymphoma using the immune microenvironment and clinical factors. METHODS: A total of 127 patients with aggressive B cell lymphoma between 2014 and 2015 were enrolled in this study. CD4, Foxp3, CD8, CD68, CD163, PD-1, and PD-L1 expression levels were evaluated in paraffin-embedded lymphoma tissues to identify their roles in the risk stratification. Eleven factors were identified for further evaluation using analysis of variance, chi-square, and multinomial logistic regression analysis. RESULTS: Significant differences in 11 factors (age, Ann Arbor stage, B symptom, ECOG performance status, infiltrating CD8+ T cells, PD-L1 expression, absolute blood monocyte count, serum lactate dehydrogenase, serum iron, serum albumin, and serum β2-microglobulin) were observed among patient groups stratified by at least two risk stratification methods [International Prognostic Index (IPI), revised IPI, and NCCN-IPI models] (P < 0.05). Concordance rates were high (81.4%-100.0%) when these factors were used for the risk stratification. No difference in the risk stratification results was observed with or without the Ann Arbor stage data. CONCLUSION: We developed a convenient and inexpensive tool for use in risk stratification of aggressive B cell lymphomas, although further studies on the role of immune microenvironmental factors are needed.
OBJECTIVE: To investigate the risk stratification of aggressive B cell lymphoma using the immune microenvironment and clinical factors. METHODS: A total of 127 patients with aggressive B cell lymphoma between 2014 and 2015 were enrolled in this study. CD4, Foxp3, CD8, CD68, CD163, PD-1, and PD-L1 expression levels were evaluated in paraffin-embedded lymphoma tissues to identify their roles in the risk stratification. Eleven factors were identified for further evaluation using analysis of variance, chi-square, and multinomial logistic regression analysis. RESULTS: Significant differences in 11 factors (age, Ann Arbor stage, B symptom, ECOG performance status, infiltrating CD8+ T cells, PD-L1 expression, absolute blood monocyte count, serum lactate dehydrogenase, serum iron, serum albumin, and serum β2-microglobulin) were observed among patient groups stratified by at least two risk stratification methods [International Prognostic Index (IPI), revised IPI, and NCCN-IPI models] (P < 0.05). Concordance rates were high (81.4%-100.0%) when these factors were used for the risk stratification. No difference in the risk stratification results was observed with or without the Ann Arbor stage data. CONCLUSION: We developed a convenient and inexpensive tool for use in risk stratification of aggressive B cell lymphomas, although further studies on the role of immune microenvironmental factors are needed.